PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsInterferon alfa-2a
Interferon alfa-2a
Roferon-A (interferon alfa-2a) is a protein pharmaceutical. Interferon alfa-2a was first approved as Roferon-a on 1986-06-04. It is used to treat brain neoplasms, chronic hepatitis c, colorectal neoplasms, cryoglobulinemia, and essential thrombocythemia amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
digestive system diseasesD004066
nervous system diseasesD009422
eye diseasesD005128
urogenital diseasesD000091642
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
immune system diseasesD007154
Show 1 more
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Interferon alfa-2a
Tradename
Proper name
Company
Number
Date
Products
Roferon-Ainterferon alfa-2aRocheN-103145 DISCN1986-06-04
1 products
Hide discontinued
Labels
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L03: Immunostimulants
L03A: Immunostimulants
L03AB: Interferons
L03AB04: Interferon alfa-2a
HCPCS
Code
Description
S0145
Injection, pegylated interferon alfa-2a, 180 mcg per ml
Clinical
Clinical Trials
462 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HepatitisD006505K75.914125868947343
Hepatitis aD006506EFO_0007305B1511104748842305
Hepatitis cD006526B19.21096776830269
Chronic hepatitis cD019698EFO_0004220B18.2759555224189
Chronic hepatitisD006521K73.9839303916122
Hepatitis bD00650962814261784
Chronic hepatitis bD019694EFO_0004239B18.163113281284
Hiv infectionsD015658EFO_0000764B2071895338
InfectionsD007239EFO_00005443187329
CarcinomaD002277C80.0186115
Show 23 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Herpesviridae infectionsD006566EFO_0007309B00.433
Major depressive disorderD003865EFO_0003761F22123
SarcomaD012509213
Kaposi sarcomaD012514C46213
Breast neoplasmsD001943EFO_0003869C50112
Multiple myelomaD009101C90.022
Plasma cell neoplasmsD05421922
Lymphoid leukemiaD007945C91122
AdenocarcinomaD00023011
Brain neoplasmsD001932EFO_0003833C7111
Show 40 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients516
PsoriasisD011565EFO_0000676L4022
Liver failureD017093K72.911
Hepatic insufficiencyD04855011
Alcoholic liver cirrhosisD008104EFO_1000802K70.311
Plexiform neurofibromaD018318EFO_000065811
NeurofibromaD009455EFO_000062211
Papillomavirus infectionsD03036111
Anus neoplasmsD001005EFO_0003835C2111
Squamous cell carcinomaD00229411
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameInterferon alfa-2a
INN
Description
Pegylated interferon alfa-2a, sold under the brand name Pegasys among others, is medication used to treat hepatitis C and hepatitis B. For hepatitis C it is typically used together with ribavirin and cure rates are between 24 and 92%. For hepatitis B it may be used alone. It is given by injection under the skin.
Classification
Protein
Drug class
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI120608
ChEMBL IDCHEMBL2108508
ChEBI ID
PubChem CID
DrugBankDB00008
UNII ID
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 42 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
30,555 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use